Verify any claim · lenz.io
Claim analyzed
Health“As of May 7, 2026, the case-fatality rate of Hantavirus Pulmonary Syndrome in the United States is about 35%.”
Submitted by Vicky
The conclusion
The best U.S. evidence places HPS case-fatality in the mid-to-high 30s, so “about 35%” is broadly accurate. A 1993–2024 summary reports 34.9%, while CDC public-facing materials often round higher, to roughly 38–40%. The claim is reasonable as an approximation, but it understates the higher figure often used by CDC.
Caveats
- CDC sources do not present one single number; public guidance often says roughly 38–40%, while surveillance summaries can be closer to 35%.
- Some CDC pages report broader “hantavirus disease” data rather than HPS-only data, so denominators and labels are not always identical.
- Annual case-fatality rates can swing because U.S. hantavirus case counts are small; long-run cumulative estimates are more reliable than single-year snapshots.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
HPS is fatal in nearly 4 in 10 people who are infected.
The age-adjusted death rate decreased 3.8% from 750.5 deaths per 100,000 U.S. standard population in 2023 to 722.1 in 2024. In 2024, a total of 3,072,666 resident deaths were registered in the United States—18,298 fewer deaths than in 2023.
HPS can be deadly. Thirty-eight percent of people who develop respiratory symptoms may die from the disease.
Although rare, Hantavirus Pulmonary Syndrome (HPS) is frequently fatal, with a case fatality rate of 36%.
As of the end of 2022, 864 cases of hantavirus disease were reported in the United States since surveillance began in 1993. Cases of hantavirus infection resulting in death: 35%. Cases of hantavirus infection occurring west of the Mississippi River: 94%.
In the past 20 years of surveillance for hantavirus in humans in the United States, 624 cases of hantavirus pulmonary syndrome (HPS) have been reported.
The overall case-fatality rate was 35%. The HPS case-fatality rate in the United States was 35% during 1993–2009. Despite its rarity, HPS continues to occur in the United States. With a case-fatality rate of 35%, HPS remains 1 of the most severe infectious diseases endemic to the United States.
Hantavirus pulmonary syndrome (HPS) has a case-fatality rate of approximately 38% in the Americas. In the United States, the overall CFR for HPS remains around 36% based on cases reported up to 2024.
As of June 6, 2002, a total of 318 cases of HPS have been identified in 31 states, with a case fatality of 37%. Only 20–50 cases of HPS have been confirmed annually in the United States since the disease was described in 1993.
In the year 2020, 833 cases of hantavirus infection had been reported, with 35% mortality rate in the US. Hantavirus disease surveillance in the United States began in 1993 during an outbreak of severe respiratory illness in the four corners region.
Overall, mortality is 1 to 15%, almost always occurring in patients with the more severe forms. Case fatality rates of up to 50% occur with more severe disease. However, without early treatment, HPS fatality rate is nearly 40%.
From 1993 through 2024, 850 confirmed HPS cases were reported in the US with 297 deaths, yielding a case-fatality rate of 34.9%. Recent years (2020-2024) show a stable CFR of 33-37%.
Hantaviruses cause two syndromes, though only one is common in the United States and it is called hantavirus pulmonary syndrome (HPS). But even in this area, it often doesn’t occur and only 864 cases have been identified between 1993 and 2022.
The United States reported seven confirmed cases and two deaths (case fatality rate 29%) have been reported in the following States: Arizona (n= 3), Colorado (n= 1), Nevada (n= 1), Washington (n= 1), and Wisconsin (n= 1). This is a case fatality rate of nearly 26 percent.
The case fatality rate for HPS varies depending on the specific hantavirus strain and clinical presentation. The Sin Nombre virus, responsible for most North American HPS cases, has historically shown fatality rates ranging from 35–38% among confirmed cases. However, the CDC's official current guidance emphasizes 38% as the primary figure for respiratory HPS cases, while overall hantavirus disease (including non-pulmonary forms) averages approximately 35% across all reported cases since 1993.
According to the CDC data, 864 cases of the hantavirus disease were reported in the United States between 1993 and 2022. Hantavirus can be extremely fatal, with a 35 percent mortality rate since 1993.
The mortality rate for HPS is approximately 35%.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
Multiple high-authority sources quantify U.S. HPS case-fatality in the mid-to-high 30s: CDC pages cite ~36% (Source 4) and ~38%/“nearly 4 in 10” (Sources 1,3), while CDC surveillance and peer-reviewed summaries report ~35% (Source 5; 34.9% through 2024 in Source 12; 35% in Source 7), so the evidence supports a range rather than a single exact value. Because “about 35%” is within the well-supported 33–38% band and matches at least one CDC quantitative figure and a 1993–2024 calculation, the claim is mostly true, though it slightly downplays CDC's more common rounded public figure (~38%).
Expert 2 — The Context Analyst
The claim omits that CDC's public-facing HPS guidance commonly frames fatality as closer to ~38–40% (“nearly 4 in 10” and “38%…may die”), and that different CDC pages mix “HPS” with broader “hantavirus disease” surveillance summaries, which can yield slightly different rounded CFRs (35% vs 36–38%) depending on case definitions and time windows (Sources 1, 3, 4, 5, 8). With full context, however, the best HPS-specific cumulative estimate through 2024 is 34.9% (Source 12) and CDC surveillance also reports 35% deaths overall (Source 5), so describing the U.S. HPS case-fatality rate as “about 35%” remains broadly accurate though somewhat lower than other common CDC/WHO roundings.
Expert 3 — The Source Auditor
The most reliable sources here are CDC pages and CDC surveillance data (Sources 1, 3, 4, 5) plus WHO (Source 8) and peer‑reviewed PMC articles (Sources 7, 12); taken together, they place U.S. HPS case-fatality in the mid-to-high 30s—CDC commonly states ~38–40% for HPS (Sources 1, 3) while CDC surveillance/definitions and peer-reviewed summaries report ~35–36% (Sources 4, 5, 12) and WHO summarizes ~36% through 2024 (Source 8). Because the best evidence does not uniquely support 35% as the current HPS CFR and more current/high-authority summaries cluster around ~36–38%, the claim "about 35%" is directionally close but somewhat understates the central figure and is therefore misleading rather than clearly true.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
The CDC's own surveillance data (Source 5) explicitly states that 35% of reported U.S. hantavirus cases resulted in death, and this figure is corroborated by the peer-reviewed study in PMC covering 1993–2009 (Source 7), which found an overall case-fatality rate of exactly 35%, as well as Source 12, which calculated a CFR of 34.9% across 850 confirmed cases through 2024. Multiple highly authoritative and independent sources—including the CDC, WHO (Source 8), and peer-reviewed literature (Sources 7, 10, 12)—consistently converge on approximately 35% as the established case-fatality rate for HPS in the United States, making this figure well-supported and accurate as of May 7, 2026.
The Proponent's argument equivocates between “hantavirus disease” and HPS: CDC's surveillance page reports 35% deaths for all reported U.S. hantavirus disease cases (Source 5), while CDC's HPS-specific public guidance and definitions repeatedly place HPS fatality higher—“nearly 4 in 10” (Source 1), 38% among those with respiratory symptoms (Source 3), and 36% in the HPS case definition (Source 4)—so treating 35% as the current HPS CFR is a category error. Moreover, even the Proponent's own cited synthesis does not “converge” on 35% because WHO summarizes the U.S. HPS CFR as ~36% through 2024 (Source 8), meaning “about 35%” understates the most authoritative, up-to-date HPS-specific figures rather than matching them.
Argument against
The motion is false because the CDC's current public-facing guidance does not support “about 35%” for HPS; it repeatedly places HPS fatality closer to ~38–40% ("nearly 4 in 10" in the CDC clinician brief, Source 1; "Thirty-eight percent" in CDC About Hantavirus, Source 3; and 37% in the CDC MMWR summary, Source 9). Even CDC's own surveillance framing conflicts with the motion's precision: CDC's case definition cites 36% (Source 4) and WHO summarizes the U.S. CFR as ~36% through 2024 (Source 8), so “about 35%” is an underestimation relative to the most authoritative, up-to-date figures in the brief.
The Opponent selectively emphasizes rounded approximations from CDC public-facing language (Sources 1, 3) while ignoring that CDC's own surveillance data (Source 5) explicitly records 35% as the precise case-fatality figure, and the peer-reviewed epidemiological study covering 1993–2024 (Source 12) independently calculated a CFR of 34.9%—figures that are mathematically consistent with 'about 35%.' Furthermore, the Opponent commits a false precision fallacy by treating figures of 35%, 36%, 37%, and 38% as meaningfully distinct when all fall within the natural statistical variation of a rare disease with under 900 total reported cases, meaning 'about 35%' accurately characterizes the established range rather than constituting an underestimation.